174 related articles for article (PubMed ID: 35989867)
1. Influence of Statins on the Survival Outcomes of Patients with Diffuse Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
Li Y; Zhou H; Zou L
Int J Clin Pract; 2022; 2022():5618290. PubMed ID: 35989867
[TBL] [Abstract][Full Text] [Related]
2. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era.
Nowakowski GS; Maurer MJ; Habermann TM; Ansell SM; Macon WR; Ristow KM; Allmer C; Slager SL; Witzig TE; Cerhan JR
J Clin Oncol; 2010 Jan; 28(3):412-7. PubMed ID: 20008638
[TBL] [Abstract][Full Text] [Related]
3. Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era.
Song MK; Chung JS; Lee GW; Cho SH; Hong J; Shin DY; Shin HJ
Leuk Res; 2015 Feb; 39(2):211-5. PubMed ID: 25541029
[TBL] [Abstract][Full Text] [Related]
4. Statin and cyclooxygenase-2 inhibitors improve survival in newly diagnosed diffuse large B-cell lymphoma: a large population-based study of 4913 subjects.
Smyth L; Blunt DN; Gatov E; Nagamuthu C; Croxford R; Mozessohn L; Cheung MC
Br J Haematol; 2020 Nov; 191(3):396-404. PubMed ID: 32304100
[TBL] [Abstract][Full Text] [Related]
5. Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis.
Zhou X; Ma T; Zhang Y; Zhou N; Li J
PLoS One; 2017; 12(3):e0174648. PubMed ID: 28355276
[TBL] [Abstract][Full Text] [Related]
6. Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP.
Samaras P; Heider H; Haile SR; Petrausch U; Schaefer NG; Siciliano RD; Meisel A; Mischo A; Zweifel M; Knuth A; Stenner-Liewen F; Renner C
Ann Hematol; 2010 Aug; 89(8):783-7. PubMed ID: 20204361
[TBL] [Abstract][Full Text] [Related]
7. Rituximab treatment strategy for patients with diffuse large B-cell lymphoma after first-line therapy: a systematic review and meta-analysis.
Ren YR; Jin YD; Zhang ZH; Li L; Wu P
Chin Med J (Engl); 2015 Feb; 128(3):378-83. PubMed ID: 25635435
[TBL] [Abstract][Full Text] [Related]
8. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
[TBL] [Abstract][Full Text] [Related]
9. Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China.
Wang S; Wang L; Hu J; Qian W; Zhang X; Hu Y; Zhu Q; Chen B; Wu D; Chang CH; Xu P; Zheng X; Wei J; Liu Y; Cui G; Tang Y; Ma Y; Huang H; Yi H; Zhao W
Cancer Commun (Lond); 2021 Mar; 41(3):229-239. PubMed ID: 33482051
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
[No Abstract] [Full Text] [Related]
11. The Role of Consolidative Radiotherapy after a Complete Response to Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma in the Rituximab Era: Results from a Systematic Review with a Meta-Analysis.
Hu C; Deng C; Zou W; Zhang G; Wang J
Acta Haematol; 2015; 134(2):111-8. PubMed ID: 25925586
[TBL] [Abstract][Full Text] [Related]
12. Diabetes and the Prognosis in Patients With Non-Hodgkin Lymphoma: A Meta-analysis of Cohort Studies.
Han Z; Xu H; Zhao M; Jing F; Xue H; Xiao S
Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):e77-e88. PubMed ID: 34593361
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of baseline C-reactive protein in diffuse large B-cell lymphoma: a systematic review and meta-analysis.
Huang Z; Wang K; Huang S; Lu Q
Transl Cancer Res; 2023 Aug; 12(8):2169-2180. PubMed ID: 37701105
[TBL] [Abstract][Full Text] [Related]
14. [Research of prognostic immunophenotypes in 163 patients of diffuse large B-cell lymphoma].
Yang X; Chen S; Qi Y; Xu XY; Guan X; Yang YC; Liu YX; Guo YH; Gong WC; Gao YN; Wang XH; Li W; Li LF; Fu K; Zhang HL; Meng B
Zhonghua Xue Ye Xue Za Zhi; 2021 Jun; 42(6):487-494. PubMed ID: 34384155
[No Abstract] [Full Text] [Related]
15. Influence of statin use on prognosis of patients with renal cell cancer: a meta-analysis.
Liang W; Pan Y; Liu A; He Y; Zhu Y
Front Oncol; 2023; 13():1132177. PubMed ID: 37519780
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of red blood cell distribution width and D-Dimer in diffuse large B-cell lymphoma: Systematic review and meta-analysis.
Rahchamani M; Sedghi M; Hakimi A; Nejatianfar M; Javaheri T; Tavakoli R; Ahmadi R; Makarem M; Azmi-Naei N; Zahmatkesh Sangani S; Kamandi N; Soleimanian A; Shavaleh R; Foogerdi M; Rahmani K
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1936. PubMed ID: 37997648
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis.
Guo B; Tan X; Ke Q; Cen H
PLoS One; 2019; 14(1):e0210224. PubMed ID: 30625203
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of geriatric nutritional risk index in patients with diffuse large B-cell lymphoma: a meta-analysis.
Yan C; Xie Y; Hua Y; Li S; Fu H; Cheng Z; Wu J
Clin Transl Oncol; 2024 Feb; 26(2):515-523. PubMed ID: 37438653
[TBL] [Abstract][Full Text] [Related]
19. Whether statin use improves the survival of patients with glioblastoma?: A meta-analysis.
Xie Y; Lu Q; Lenahan C; Yang S; Zhou D; Qi X
Medicine (Baltimore); 2020 Feb; 99(9):e18997. PubMed ID: 32118710
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
